EMA grants Orphan Drug Designation for Setmelanotide for treatment of acquired hypothalamic obesity
The European Medicines Agency (EMA) has issued a positive opinion on the Rhythm Pharmaceuticals’ orphan drug designation request for...
top of page
Browse by category
Search
Browse by tag
bottom of page